Cardiff and Vale University Health Board
Medical genetic testing kits
This is a contract result notice, not an open opportunity. Details from the official award data.
The procurement contact named on the official notice.
The All Wales Medical Genomics Service (AWMGS) has routinely utilised Multiplex Ligation-Dependent Probe Amplification (MLPA) as a diagnostic tool for identifying Copy Number Variations (CNVs)—including deletions and duplications—across a range of genetic disorders.
This testing supports clinical decision-making and patient treatment strategies.MLPA technology involves the use of oligonucleotide probe pairs that hybridise to specific DNA sequences within target genes.
When both probes bind adjacently at a site of interest, they are ligated and subsequently amplified via Polymerase Chain Reaction (PCR).
The amplified DNA fragments are then separated by capillary electrophoresis and analysed to detect CNVs.Since its inception, AWMGS has exclusively sourced MLPA probes and reagents from MRC Holland, a Netherlands-based supplier recognised for its specialised products in molecular diagnostics.
Make the case to bid
Reveal who to approach at Cardiff and Vale University Health Board, and generate a go-to-market strategy from their news, accounts and people.
Free to start. Named contacts come from published notices; the strategy is generated from the buyer’s news, accounts and people.
- OCID
- ocds-h6vhtk-05a434
- Stage
- award · Awarded
- Source
- Find a Tender
- Buyer ref
- 050045-2026
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Medical Equipment & Pharmaceuticals
Cardiff and Vale University Health Board’s tender network